⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Data from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth

Hilary A. Kenny Carman Ka Man Ip Lucy Kelliher Tejas Samantaray Kasjusz Kordylewicz Rachael Hoffmann Sarah Rauch Beatrice Malacrida Sophie L.P. Skingsley Frances R. Balkwill Chiara Battistini Ugo Cavallaro Wolf R. Wiedemeyer Ernst Lengyel

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Navitoclax and YM155 combined with carboplatin significantly inhibit ovarian cancer tumor growth.
KEY EVIDENCE: The combination therapy reduced tumor size by about 40% in treated groups compared to controls.
APPROACH: The study used in vivo models to test the efficacy of these inhibitors against ovarian cancer.
SIGNIFICANCE: This research opens pathways for more effective therapies targeting multiple pathways in ovarian cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Experimental combination therapy shows increased efficacy against ovarian cancer tumors, suggesting new treatment options.

Abstract

Supplemental methods and references

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kenny et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d031b https://doi.org/10.1158/1535-7163.29759647

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
2Supplemental Figure 11 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
3Supplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
4Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
5Supplemental Figure 5 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025

More related papers

Supplemental Figure 14 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 8 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025